The short answer
Aloe gel may change glucose control, but extra hypoglycemia with insulin aspart has not been demonstrated. Aloe preparation matters, especially the distinction between gel and laxative latex.
What this answer covers
Oral Aloe vera inner-leaf gel evidence; latex, whole leaf, topical gel and blends are different exposures.
- Supplement or preparation
- Aloe vera
- Medication ingredient
- insulin aspart, human
A human trial used other diabetes medicines
A small study added aloe gel to glyburide and metformin and found improved glucose measures. It reported no adverse effects in the abstract, but it was not an insulin-aspart trial and cannot establish the safety of that combination.
Glucose improvement is not proof of hypoglycemia
The study evaluated diabetes control, not an aspart-specific rate of dangerously low glucose. Insulin aspart already carries that risk, so adding a glucose-active product deserves review without presenting the interaction as proven.
Gel and latex are different
The evidence concerns oral gel. Latex can cause diarrhea, and whole-leaf preparations have a different composition. A topical product cannot be treated as the same exposure as an oral supplement.
Keep the insulin plan product-specific
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. NovoLog and Fiasp have different meal-timing instructions; an aloe study does not change them.
Evidence and practical considerations
Side effects & toxicity
Indirect oral-drug aloe-gel evidence does not establish added clinical hypoglycemia with insulin aspart.
- Exact scope
- Oral Aloe vera inner-leaf gel evidence; latex, whole leaf, topical gel and blends are different exposures. with Insulin aspart human RxCUI51428 IN; NovoLog/Fiasp formulation and subcutaneous/pump/supervised intravenous routes distinguished.
- Medication form and route
- injected insulin aspart; oral supplement
What remains uncertain
- No source-specific uncertainty removed; no invented event rate or universal insulin adjustment.
Factors that may matter: Exact insulin product; Meal pattern; Dose; Other diabetes treatment; Kidney and liver function; Supplement preparation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Hyperlipidemic type2diabetes adults;30aloe and30placebo.
Aloe gel improved glucose measures with oral diabetes medicines; no adverse effects reported in the abstract.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not insulin aspart. Small trial and absence of reported adverse effects do not establish a hypoglycemia risk rate or cover latex/whole-leaf products.
Source 4: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering different Aloe vera products.
Guidance distinguishes oral preparations and describes limited glucose-lowering research; latex can cause abdominal pain, cramps and diarrhea.
How this applies: Indirect for exact insulin aspart; source medication and supplement formulation are preserved.
General guidance is not a glimepiride interaction study or evidence that different aloe products are interchangeable. This does not establish an exact insulin-aspart interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact insulin-aspart article with product, route, botanical and clinical endpoint boundaries. | |
| Research summary published |
Article revision: 28036d692ba94ffa
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.